CEBPA and acute myeloid leukemia: For example, mutations in NPM1 and CEBPA are associated with a good prognosis in CN-AML [12, 13], whereas DNMT3, TET2, and RUNX1 mutations are associated with poor prognosis in CN-AML [14–16].